Objective-To study how Niemann-Pick disease type C1 (NPC1) influences hepatic triacylglycerol (TG) metabolism and to determine whether this is reflected in circulating lipid levels. Methods and Results-In Npc1 Ϫ/Ϫ mice, the hepatic cholesterol content is increased but the TG content is decreased. We investigated lipid metabolism in Npc1 Ϫ/Ϫ mouse hepatocytes and the association of NPC1 single-nucleotide polymorphisms with circulating TGs in humans. TGs were reduced in Npc1 Ϫ/Ϫ mouse serum and hepatocytes. In Npc1 Ϫ/Ϫ hepatocytes, the incorporation of [ 3 H]oleic acid and [ 3 H]acetate into TG was decreased, but shunting of oleic acid-or acetate-derived [ 3 H]carbons into cholesterol was increased. Inhibition of cholesterol synthesis normalized TG synthesis, content, and secretion in Npc1 Ϫ/Ϫ hepatocytes, suggesting increased hepatic cholesterol neogenesis as a cause for the reduced TG content and secretion. We found a significant association between serum TG levels and 5 common NPC1 single-nucleotide polymorphisms in a cohort of 1053 men, with the lowest Pϭ8.7ϫ10 Ϫ4 for the single-nucleotide polymorphism rs1429934. The association between the rs1429934 A allele and higher TG levels was replicated in 2 additional cohorts, which included 8041 individuals. Conclusion-This study provides evidence of the following: (1) in mice, loss of NPC1 function reduces hepatocyte TG content and secretion by increasing the metabolic flux of carbons into cholesterol synthesis; and (2) common variation in NPC1 contributes to serum TG levels in humans. (Arterioscler Thromb Vasc Biol. 2010;30:1614-1620.) 
N iemann-Pick disease type C (NPC) is a rare autosomal recessive lipidosis, with most patients characterized by progressive neurological disease developing in late childhood. Patients suffering from the neonatal disease typically die of liver failure by the age of 6 months, and most patients with milder disease experience liver dysfunction. 1 More than 95% of the cases result from mutations in the NPC1 gene that encodes a large integral membrane protein of late endocytic organelles. The NPC1 protein is thought to be involved in the export of cholesterol and/or other lipids from these organelles. In the absence of NPC1 function, the cholesterol homeostatic machinery in the endoplasmic reticulum fails to sense the increased cholesterol levels, and cholesterol biosynthesis and uptake are inappropriately increased. 1, 2 The liver plays a key role in the maintenance of whole body lipid balance. Hepatocytes take up cholesterol and triacylglyc-erols (triglycerides [TGs]), in particular via endocytosis of low-density lipoproteins (LDLs) and of chylomicron remnants postprandially, 3 and secrete cholesterol and TG in very-low density lipoproteins (VLDLs). 4 When there is an excess of lipid, lipid droplets provide a cytoplasmic deposit for TG and fatty acid esters of cholesterol (cholesteryl esters [CEs] ). The Npc1 Ϫ/Ϫ mouse develops a liver disease similar to that in infants with NPC and provides a model for studying hepatic dysfunction in the disease. 5, 6 In Npc1 Ϫ/Ϫ mouse liver, LDL uptake and cholesterol biosynthesis are increased. 7 The role of NPC1 in cholesterol homeostasis has received considerable attention; however, whether NPC1 contributes to TG metabolism is largely unexplored. In Npc1 Ϫ/Ϫ mice, a reduced TG content was found in the liver 5 and in isolated hepatocytes. 8 The underlying reason is not known. The amount of mature sterol regulatory element binding protein (SREBP)-1, a key regulator of fatty acid synthesis, was elevated in Npc1 Ϫ/Ϫ hepatocytes 8 ; however, the rate of fatty acid synthesis in Npc1 Ϫ/Ϫ liver was decreased. 5 Furthermore, it was reported that in Npc1 Ϫ/Ϫ liver, late endocytic organelles contain elevated levels of free fatty acids, suggesting that lysosomal fatty acid egress may be impaired. 9 However, in the fibroblasts of patients with NPC1, the flux of fatty acids through lysosomes was normal. 10 There is also little information on the effects of NPC1 on blood lipids in humans. High-density lipoprotein cholesterol levels were decreased in patients with NPC. 11, 12 To our knowledge, no reports on the effects of NPC1 gene variation on serum lipid levels at the population level are available.
To elucidate the mechanisms underlying the TG imbalance in Npc1 Ϫ/Ϫ liver, we studied fatty acid use and TG synthesis and secretion in Npc1 Ϫ/Ϫ hepatocytes. We also analyzed common genetic variations in the NPC1 gene and their association to serum lipids in 3 independent population cohorts. Our results suggest that the loss of NPC1 function alters hepatic TG metabolism by increasing the flux of carbons into sterol biosynthesis at the expense of TG and provide evidence that common variation in NPC1 contributes to circulating TG levels in humans.
Methods
A detailed "Methods" section is online (all supplemental material is available at http://atvb.ahajournals.org).
Mice and Hepatocytes
Npc1 ϩ/ϩ and Npc1 Ϫ/Ϫ Balb/C mice were bred, genotyped, and maintained on a chow diet (Altromin 1320 Mouse Maintenance Diet), as described previously, 13 and analyzed at the age of 6 to 7 weeks. The experimental protocols were approved by the institutional animal care and use committee. Primary mouse hepatocytes were isolated using the collagenase perfusion method and cultured for up to 24 hours, as previously described. 14 Where indicated, culture medium was supplemented with 20-mol/L lovastatin and 50-mol/L mevalonate (the latter to support cell viability 15 ). Sucrose gradient ultracentrifugation of the media from both genotypes showed that approximately 98% of secreted TG and approximately 60% of apolipoprotein B (ApoB) floated to the top of the gradient (not shown), strongly suggesting that the TG in the culture media was associated with VLDL particles. 16 No sex differences were observed in the parameters analyzed, and the experimental groups consisted of equal or nearly equal numbers of males and females, except in the last figure in which only males were used.
Human Samples
Clinical data and blood samples for DNA extraction from the third cycle of investigations (at the age of 71 years) were used from the Uppsala Longitudinal Study of Adult Men (ULSAM; more information available at http://www.pubcare.uu.se/ULSAM). 17, 18 The Fragmin and Fast Revascularization during Instability in Coronary Artery Disease (FRISC) II is a Scandinavian multicenter randomized trial on the treatment of unstable coronary artery disease, 19 and the Sweden Women and Men and Ischemic Heart Disease (SWISCH) investigation included healthy individuals of a similar age as the FRISC II patients. 20, 21 The Malmö Diet and Cancer Study (MDC) is a population-based prospective cohort from Malmö, Sweden, and the MDC-CC is a random subsample of individuals evaluated to characterize cardiovascular and metabolic risk factors. 22, 23 Blood samples for DNA extraction were drawn on recruitment to the studies. Samples were taken after overnight fasting, except in FRISC II. All individuals gave their written consent, and the studies were approved by the respective ethical review boards. DNA was available for the current study from 1053 ULSAM, 2952 FRISC II/SWISCH, and 5506 MDC-CC study subjects.
Results

Decreased TG Content in Npc1 ؊/؊ Mouse Liver, Hepatocytes, and Serum
The liver is the organ in the Npc1 Ϫ/Ϫ mouse with the most prominent cholesterol deposition. 24 This storage was readily visualized by staining of liver sections from 6-to 7-week-old mice with the fluorescent sterol-binding agent filipin ( Figure  1A) . In contrast, lipid droplets in the Npc1 Ϫ/Ϫ mouse liver were drastically depleted, as judged by Oil Red O staining ( Figure 1A ). At this age, food intake, 24 intestinal fatty acid absorption, 25 and body weight 13 are not affected in Npc1 Ϫ/Ϫ mice; however, the liver pathological features are already evident. 5, 6 The lipid imbalance was confirmed by lipid mass determinations, showing a massive increase in free cholesterol and an approximately 80% reduction in TG ( Figure 1B) . No difference in the hepatic CE content was observed (3.30Ϯ0.64-ng/g protein in Npc1 ϩ/ϩ mice versus 2.90Ϯ0.33-ng/g protein in Npc1 Ϫ/Ϫ mice), implicating that the depletion of lipid droplets is because of the reduction in TG. The amount of the lipid droplet-associated protein perilipin 2/adipocyte differentiation related protein (ADRP) in Npc1 Ϫ/Ϫ liver was reduced to less than 10% of that in Npc1 ϩ/ϩ liver ( Figure 1C ).
Next, we isolated primary hepatocytes from 6-to 7-weekold Npc1 ϩ/ϩ and Npc1 Ϫ/Ϫ mice and analyzed their lipid content. The lipid imbalance was also observed in Npc1 Ϫ/Ϫ hepatocytes, although the decrease in TG was smaller than in the intact tissue ( Figure 2A ). Primary hepatocytes are capable of secreting VLDL. Therefore, the hepatocyte medium was analyzed to obtain information about lipid secretion. We found increased secretion of free cholesterol, CE, and the VLDL apolipoprotein ApoB from Npc1 Ϫ/Ϫ hepatocytes (Figure 2A ), in accordance with previous results. 8 Interestingly, we also observed less TG in Npc1 Ϫ/Ϫ hepatocyte medium (Figure 2A ), suggesting that the decreased cellular TG content was paralleled by decreased TG secretion. No changes in hepatocyte TG secretion were observed, despite markedly reduced TG levels in Npc1 Ϫ/Ϫ hepatocytes in 8. The reason for this difference versus our results is not known but may be related to the cell culture conditions.
To assess whether the hepatic lipid imbalance in Npc1 Ϫ/Ϫ mice is reflected in blood lipids, serum lipid concentrations were measured. An increase in total cholesterol was observed in Npc1 Ϫ/Ϫ mice ( Figure 2B ), consistent with previous data. 6 In addition, we found that serum TGs were decreased in Npc1 Ϫ/Ϫ mice ( Figure 2B ).
Increased Fatty Acid Use for Cholesterol Synthesis in Npc1 ؊/؊ Hepatocytes
To gain further insight into the altered TG metabolism in Npc1 Ϫ/Ϫ hepatocytes, we studied the metabolism of incoming fatty acids. Thus, we labeled LDL with cholesteryl [ 3 H]oleate and incubated it with hepatocytes for 3 hours, followed by 3 hours in the absence of LDL. During the 3-hour labeling, LDL was endocytosed and cholesteryl [ Figure 3A) .
To investigate if the altered fatty acid use in Npc1 Ϫ/Ϫ hepatocytes applied to other than LDL-derived fatty acids, we labeled hepatocytes with [ 3 H]oleate complexed to albumin and analyzed the incorporation of radioactivity into major cellular lipids. Less radioactivity was recovered in TGs in Npc1 Ϫ/Ϫ versus Npc1 ϩ/ϩ hepatocytes ( Figure 3B ). We also found an increased partitioning of [ 3 H]carbons into cholesterol and CEs ( Figure 3B ). Although the [ 3 Figure 3A ).
Altered Use of Acetate for Lipid Biosynthesis in Npc1 ؊/؊ Hepatocytes
The specific activity of the precursor pool of acetyl-CoA giving rise to cholesterol depends on its source. To more directly assess if the use of acetate differs between Npc1 ϩ/ϩ and Npc1 Ϫ/Ϫ hepatocytes, we labeled the cells with [ 3 H]acetate and analyzed the partitioning of radioactivity into major lipid classes. We found that the incorporation of [ 3 H]acetate into TG was markedly decreased in Npc1 Ϫ/Ϫ hepatocytes, whereas its incorporation into cholesterol and choline phospholipids (PC and SM) was increased ( Figure 3C ). (In contrast, [ 3 H]acetate incorporation into phosphatidyl ethanolamine, phosphatidyl serine, and phosphatidyl inositol was unaltered [data not shown]). This is consistent with the enhanced cholesterol and phosphatidylcholine synthesis in Npc1 Ϫ/Ϫ hepatocytes. 7, 8 Together, these results indicate that the metabolism of incoming fatty acids differs between Npc1 ϩ/ϩ and Npc1 Ϫ/Ϫ hepatocytes and speak for an increased flux of [ 3 H] carbons into cholesterol and choline phospholipids at the expense of TG in Npc1 Ϫ/Ϫ hepatocytes. However, we cannot exclude the possibility that Npc1 ϩ/ϩ and Npc1 Ϫ/Ϫ hepatocytes may have different pool sizes of unlabeled hydrocarbon metabolites, affecting the partitioning of the [ 3 H] carbons.
To investigate if Npc1 Ϫ/Ϫ hepatocytes are compromised in their ability to synthesize (unlabeled) TG in the presence of ample exogenous substrate, we incubated Npc1 ϩ/ϩ and Npc1 Ϫ/Ϫ cells with 400-mol/L oleic acid/BSA complex for 16 hours. This roughly tripled the TG mass in both genotypes (with 161.0Ϯ26.0-ng/g protein in Npc1 ϩ/ϩ and 156.0Ϯ7.0ng/g protein in Npc1 Ϫ/Ϫ cells). However, when the exogenous fatty acid was removed, the Npc1 ϩ/ϩ hepatocytes continued to accumulate TG for several hours, whereas in Npc1 Ϫ/Ϫ cells, no further increment in TG was observed ( Figure 4 ). Together, these results show that the machinery for TG biosynthesis is fully functional in Npc1 Ϫ/Ϫ hepatocytes. However, their fatty acid use differs from the wild type.
Inhibition of Cholesterol Synthesis Corrects the TG Imbalance in Npc1 ؊/؊ Hepatocytes
If the increased shunting of fatty acids for cholesterol production is an important parameter underlying the TG reduction in Npc1 Ϫ/Ϫ hepatocytes, blocking cholesterol synthesis should normalize TG metabolism in these cells. Indeed, when the fatty acid-induced accumulation of TG in Npc1 Ϫ/Ϫ hepatocytes was analyzed in the presence of lovastatin (an inhibitor of hydroxymethylglutaryl CoA reductase, the ratelimiting enzyme of cholesterol biosynthesis), the TG deposition in these cells was rescued (Figure 4) .
To further test this possibility, we treated hepatocytes cultured in normal growth medium with lovastatin and analyzed the changes in cellular and secreted lipids. In Npc1 ϩ/ϩ hepatocytes, statin reduced cholesterol in the cells ( Figure 5A ) and TG in the medium ( Figure 5B ). In contrast, in Npc1 Ϫ/Ϫ cells, statin increased both the cellular and medium TG content and eliminated the difference between the genotypes ( Figure 5B ). These findings show that inhibition of cholesterol biosynthesis normalizes the cellular TG content and increases TG secretion in Npc1 Ϫ/Ϫ hepatocytes, therefore suggesting that the increased cholesterol synthesis largely explains the reduced TG content and secretion in these cells.
Association of NPC1 Single-Nucleotide Polymorphisms With Serum TG Levels in Human Population Cohorts
To explore if common genetic variation in the NPC1 gene is associated with serum lipid levels in humans, we selected 18 single-nucleotide polymorphisms (SNPs) with minor allele frequencies of greater than 0.1 that were located throughout the NPC1 gene, with an average spacing of 3 kb (supplemental Figure) . These SNPs were genotyped in the population-based ULSAM cohort of 1053 men. 18 A nucleotide variant (C/T; P237S), previously considered as one of the recessive NPC1 mutations but one that we observed to occur at an allele frequency of 0.02 in the general population, 26 was also genotyped. The effect of the SNP genotypes on variation in LDLcholesterol, high-density lipoprotein cholesterol, total cholesterol, and TG levels was determined using ANOVA, with body mass index, lipid medication, and diabetes mellitus as covariates.
The SNP genotypes were also tested against ApoB levels in a subsample of the ULSAM subjects for whom these values were available. An association (PϽ0.05) with serum TG levels was observed for 5 of the SNPs (rs1788825, rs1788821, rs1788785,  rs1788826, and rs1429934) , with the lowest (PϽ0.001) for SNP rs1429934 (Table) . A similar association was also observed between these SNPs and ApoB levels. These 5 SNPs are distributed throughout the NPC1 gene at a spacing of 8.3 to 14.4 kb and are in high pairwise linkage disequilibrium (r 2 ϭ0.91 to 0.98) (supplemental Table II ). An association signal (Pϭ0.04) was also observed between the P237S SNP and LDL-cholesterol (Table) , and there was a trend for an association with LDL-cholesterol for 6 other common SNPs, which are in similar highlinkage disequilibrium with each other (r 2 ϭ0.91 to 0.98).
To further explore the association between variation in the NPC1 gene and serum TG levels, we genotyped the NPC1 rs1429934 in 2 additional Swedish population cohorts, with a total of 8041 individuals. DNA samples from 2882 individuals participating in the FRISC II and SWISCH studies 19 and DNA samples from 5159 individuals participating in the MDC Cardiovascular Cohort (CC) 22, 23 were analyzed. In both replication cohorts, we found an association between the Table III ). No significant associations with total cholesterol, high-density lipoprotein cholesterol, or LDL-cholesterol were found in either cohort (supplemental Table III ).
Discussion
This study demonstrates that NPC1, a key protein implicated in cholesterol transport, affects hepatic TG metabolism, and provides evidence that NPC1 is relevant for controlling serum TG levels in mice and potentially in humans. The TG content was significantly reduced in the Npc1 Ϫ/Ϫ mouse serum, liver, and isolated hepatocytes relative to Npc1 ϩ/ϩ littermates receiving a chow diet, in accordance with the reported decrease in TG in Npc1 Ϫ/Ϫ liver 5 and hepatocytes. 8 In principle, the reduced TG content in Npc1 Ϫ/Ϫ hepatocytes could result from reduced TG synthesis, increased hydrolysis, and/or increased export as VLDL. Our data suggest that reduced TG synthesis plays an important role, as judged by the decreased incorporation of radiolabeled fatty acid and acetate into TG and the decreased accumulation of TG after loading with excess exogenous fatty acid. We failed to produce efficient TG hydrolysis in hepatocytes during the 24-hour culture in vitro, leaving increased hydrolysis as an additional possibility. On the other hand, the reduced TG secretion from Npc1 Ϫ/Ϫ hepatocytes speaks against increased TG export as VLDL as an underlying cause. One possible explanation for the reduced TG could be late endosomal fatty acid sequestration in Npc1 Ϫ/Ϫ hepatocytes. When expressed in Escherichia coli, the NPC1 protein was reported to transfer oleic acid. 27 Two additional pieces of evidence suggest that NPC1 may play a role in fatty acid metabolism and transport. In Npc1 ϩ/Ϫ macrophages, the incorporation of lipoprotein-derived fatty acids into phospholipids was inhibited, 28 and late endosomes from Npc1 Ϫ/Ϫ mouse liver contained elevated levels of free fatty acids. 9 However, in NPC1 patient fibroblasts, the fatty acid flux through lysosomes was normal. 10 Therefore, we assessed the metabolism of LDL-derived oleic acid in Npc1 Ϫ/Ϫ hepatocytes similarly as in fibroblasts. 10 We found that most of the LDL-derived fatty acid was converted into neutral lipids and phospholipids, speaking against a primary role for NPC1 as a late endosomal fatty acid transporter.
We found that the incorporation of [ . We considered that this might be to fuel the enhanced hepatic cholesterol production in Npc1 Ϫ/Ϫ mice. To assess this possibility, we inhibited cholesterol synthesis in Npc1 Ϫ/Ϫ hepatocytes with statin. This normalized both the intracellular and secreted TG levels, suggesting that the elevated cholesterol synthesis was indeed largely responsible for the decreased TG levels in Npc1 Ϫ/Ϫ hepatocytes. The mechanism by which fatty acid-and acetate-derived carbons are shunted for cholesterol rather than TG synthesis, is not clear. It is possible that cholesterol and/or its precursors directly inhibit TG production in Npc1 Ϫ/Ϫ cells. However, perhaps a more likely scenario is that less carbon is available for TG production as the result of the upregulation of the cholesterol biosynthesis pathway and, consequently, increased consumption of carbons for cholesterol (and phospholipid) biosynthesis. This, again, is probably driven by altered regulation at the transcriptional level, as suggested by elevated hydroxymethyl glutaryl CoA reductase mRNA levels 5 and increased SREBP-1 processing. 8 We presume that the increase in choline phospholipid synthesis might be secondary to the increased cholesterol synthesis because it was inhibited by statin (R.-L.U. and E.I., unpublished data, 2010).
This study provides the first evidence that genetic variation in the NPC1 gene contributes to the variability in serum lipid levels in human populations. In the ULSAM cohort, we initially found an association of 5 NPC1 SNPs exhibiting high pairwise linkage disequilibrium with serum TG levels. None of the SNPs reside in the coding region of the NPC1 gene (4 are intronic and 1 is in the 3Ј-untranslated region). These SNPs may affect the transcription levels, splicing of the NPC1 RNA, or the binding of small RNAs that, in turn, might affect the stability of the NPC1 transcript or the translation process. We then replicated the association of the SNP rs1429934 (with the lowest probability value in the ULSAM cohort) in 2 additional cohorts (total, 9094 individuals) demonstrating that the A allele of rs1429934 associates with higher triglyceride levels in several population cohorts. The reproducibility of this association clearly strengthens the notion that genetic variation in NPC1 represents one of the parameters contributing to TG metabolism in humans.
In conclusion, this study shows that loss of NPC1 function alters TG metabolism in murine hepatocytes by increasing the metabolic flux of carbons into cholesterol synthesis. Moreover, association studies in 3 independent population cohorts provide evidence that the NPC1 genotype contributes to serum TG levels in humans, which is consistent with the recent observation that TG levels were increased in a subset of patients with NPC1. 12 Interestingly, a decreased Npc1 gene dosage in mice was associated with weight gain. 29 Moreover, in a genomewide association study, the NPC1 locus was detected as a risk locus for morbid obesity. 30 The NPC1 SNP rs1805081 providing the strongest signal in this material was also genotyped in the ULSAM cohort; but, no association with body mass index was observed (P.L. and A.-C.S., unpublished data, 2009). Considering the small fraction of morbidly obese individuals in the ULSAM material, this is not surprising. However, based on the present study and the recent literature, 12, 29, 30 it seems that NPC1 is emerging as a player in TG metabolism and obesity.
